SANJIVANI PARANTERAL LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 184.2 INR | -1.71% |
|
-2.62% | +2.25% |
| 08/04 | Sanjivani Parenterals CFO Steps Down | MT |
| 08/04 | Sanjivani Paranteral Limited Announces Board Changes | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 306M 3.67M | Sales 2023 | 355M 4.26M | Capitalization | 414M 4.97M |
|---|---|---|---|---|---|
| Net income 2022 | 48M 576K | Net income 2023 | 45M 540K | EV / Sales 2022 | 2.32 x |
| Net Debt 2022 | 56.54M 679K | Net Debt 2023 | 21.91M 263K | EV / Sales 2023 | 1.23 x |
| P/E ratio 2022 |
13.5
x | P/E ratio 2023 |
9.19
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 50.58% |
More Fundamentals
* Assessed data
More news
| 1 day | -1.71% | ||
| 1 week | -2.62% | ||
| Current month | -2.44% | ||
| 1 month | +9.22% | ||
| 3 months | +11.27% | ||
| 6 months | +27.09% | ||
| Current year | +2.25% |
1 week
176.45
194.00
1 month
163.00204.95
Current year
122.15204.95
1 year
54.00204.95
3 years
10.64204.95
5 years
4.90204.95
10 years
3.17204.95
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 01/97/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 53 | 01/97/01 | |
| Director/Board Member | 55 | 31/15/31 | |
| Director/Board Member | 50 | 24/22/24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/24/17 | 184.2 | -1.71% | 5 822 |
| 16/24/16 | 187.4 | -1.42% | 9,118 |
| 15/24/15 | 190 | +2.67% | 10,678 |
| 14/24/14 | 185.1 | -0.32% | 11,968 |
| 13/24/13 | 185.7 | -1.80% | 9,020 |
Delayed Quote Bombay S.E., May 17, 2024 at 03:30 pm IST
More quotes
Sanjivani Paranteral Limited is engaged in the business of manufacturing pharmaceutical products. Its product category includes antibiotic, anti-emetic, non-steroidal anti-inflammatory drugs (NSAID) and analgesic, antimalarial, calcium and vitamin, sedative, steroid, cardiovascular, anti-fibrinolytic, anti-coagulant, vasoconstrictor, inotropic agent, anti-spasmodic, multivitamin, nutrition, iron, NSAID and analgesic, analgesic anti spasmodic, analgesic, and NSAID. Its antibiotic includes Netilmicin Sulphate, Amikacin Sulphate, and Gentamycin Sulphate. Its anti-emetic includes Ranitidine Hydrochloride, Metoclopramide, Ondansetron, and Promethazine. Its NSAID and analgesic includes Acetaminophen Injection and Diclofenac Sodium Injection. Its calcium and vitamin include Methylcobalamin 500 mcg/ml and Nicotinic Acid 10 mg/ml. Its sedative includes Midazolam Hydrochloride, Diazepam, and Dobutamine Hydrochloride. Its Iron includes iron Sucrose. Its analgesic includes Metamizole.
Sector
Pharmaceuticals
Calendar
22/07/2024
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +2.25% | 26.22M | |
| +31.99% | 694B | |
| +29.12% | 593B | |
| -1.62% | 371B | |
| +19.71% | 331B | |
| +6.57% | 290B | |
| +14.13% | 239B | |
| -3.11% | 209B | |
| +9.91% | 209B | |
| +7.93% | 169B |
- Stock Market
- Equities
- SANJIVIN Stock